Evidence map›Paper›PMID 42366322›Full record

ArticleGeneral thoracic and cardiovascular surgery2026

Therapeutic value of lymphadenectomy after neoadjuvant chemotherapy in esophageal squamous cell carcinoma.

Suguru Maruyama, Yoshihiko Kawaguchi, Katsutoshi Shoda, Ryo Saito, Wataru Izumo, Koichi Takiguchi, Kensuke Shiraishi, Shinji Furuya, Hidetake Amemiya, Daisuke Ichikawa

Abstract read
PubMed Publisher
In one paragraph

Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Suguru MaruyamaDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Yoshihiko KawaguchiDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Katsutoshi ShodaDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Ryo SaitoDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Wataru IzumoDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Koichi TakiguchiDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Kensuke ShiraishiDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Shinji FuruyaDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Hidetake AmemiyaDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
Daisuke IchikawaDepartment of Digestive Surgery, University of Yamanashi Hospital, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. dichikawa@yamanashi.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEsophageal squamous cell carcinoma (ESCC) is characterized by a high incidence of lymph node metastasis, and prophylactic lymphadenectomy plays a critical role in esophagectomy. However, the optimal extent of lymphadenectomy after neoadjuvant chemotherapy (NAC) remains unclear. We aimed to investigate the extent and significance of lymphadenectomy after NAC by comparing its therapeutic impact with that of upfront esophagectomy.

methodsIn total, 200 consecutive patients who underwent McKeown esophagectomy for ESCC between 2009 and 2021 were eligible. We compared the therapeutic value index (TVI) between patients who underwent esophagectomy after NAC and those who underwent upfront esophagectomy.

results96 (48.0%) patients underwent upfront esophagectomy and 104 (52.0%) patients underwent esophagectomy after NAC. In the upper mediastinum, middle/lower mediastinum, and peri-gastric regions, TVI in the NAC group was greater than that in the upfront group. In contrast, subcarinal lymphadenectomy showed no therapeutic benefit in the NAC group, and supra-pancreatic TVI was lower in the NAC group than in the upfront group (2.4 vs. 7.0). After propensity score matching (PSM), the results were essentially unchanged from those before matching. Subgroup analysis revealed almost no therapeutic benefit in the supra-pancreatic region for upper/middle thoracic tumors or early-stage cancers, whereas a benefit remained for lower thoracic tumors.

conclusionsLymphadenectomy in the upper mediastinum, middle/lower mediastinum, and peri-gastric regions remains important after NAC for ESCC. However, the apparent therapeutic value of subcarinal and supra-pancreatic lymphadenectomy was limited after NAC.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyLymph Node ExcisionNeoadjuvant TherapyAgedChemotherapy, AdjuvantFemaleHumansLymphatic MetastasisMaleMiddle AgedRetrospective StudiesTreatment OutcomeEsophageal squamous cell carcinomaMcKeown esophagectomyNeoadjuvant chemotherapyTherapeutic value index

Identifiers

PMID42366322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.